Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects

British Journal of Clinical Pharmacology

Volumn 75, Issue 1, 2013, Pages 197-207

  Ali, Zahid ^a,c   Laurijssens, Bart ^a,d   Ostenfeld, Thor ^a   Mchugh, Simon ^a   Stylianou, Anastasia ^a   Scott Stevens, Paul ^a   Hosking, Louise ^a   Dewit, Odile ^a   Richardson, Jill C ^a,b   Chen, Chao ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (China)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d BEL Pharm Consulting   (France)

Author keywords

Clinical pharmacology; First in human; GSK1482160; Il 1 ; P2X7 receptor; Population pharmacokinetic pharmacodynamic modelling

Indexed keywords

AMIDE; GSK 1482160; INTERLEUKIN 1BETA; N [[2 CHLORO 3 (TRIFLUOROMETHYL)PHENYL] METHYL] 1 METHYL 5 OXO LEVO PROLINAMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AGED; ALLOSTERIC REGULATION; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, PURINERGIC P2X7; SINGLE-BLIND METHOD;

EID: 84871151589     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04320.x     Document Type: Article

References (18)

1. Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 2011; 164 (Suppl. 1): S1-S324.
2. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002; 82: 1013-67.
3. Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G. Tissue distribution of the P2X7 receptor. Neuropharmacology 1997; 36: 1277-83.
4. Lucae S, Salyakina D, Barden N, Harvey M, Gagné B, Labbé M, Binder EB, Uhr M, Paez-Pereda M, Sillaber I, Ising M, Brückl T, Lieb R, Holsboer F, Müller-Myhsok B. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 2006; 15: 2438-45.
5. Sluyter R, Shemon A, Wiley J. Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL1β release from human monocytes. J Immunol 2004; 172: 3399-405.
6. Gu BJ, Zhang W, Worthington RA, Sluyter R, Dao-Ung P, Petrou S, Barden JA, Wiley JS. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 2001; 276: 11135-42.
7. Sim JA, Young MT, Sung H-Y, North RA, Surprenant A. Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci 2004; 24: 6307-14.
8. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Virgilio FD. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006; 176: 3877-83.
9. Engel T, Gomez-Villafuertes R, Tanaka K, Mesuret G, Sanz-Rodriguez A, Garcia-Huerta P, Miras-Portugal MT, Henshall DC, Diaz-Hernandez M. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J 2011; 26: 1616-28.
10. Arbeloa J, Pérez-Samartín A, Gottlieb M, Matute C. P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol Dis 2011; 45: 954-61.
11. Altomonte L, Zoli A, Mirone L, Scolieri P, Magaró M. Serum levels of interleukin-1β, tumour necrosis factor-α and interleukin-2 in rheumatoid arthritis. Correlation with disease activity. Clin Rheumatol 1992; 11: 202-5.
12. Al-Shukaili A, Al-Kaabi J, Hassan B. A comparative study of interleukin-1beta production and P2X7 expression after ATP stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls. Inflammation 2008; 31: 84-90.
13. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005; 114: 386-96.
14. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002; 46: 614-24.
15. Conn P, Christopoulos A, Lindsley C. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Reviews Drug Discovery. 2009; 8: 41-54.
16. Matthews PM, Rabiner I, Gunn R. Non-invasive imaging in experimental medicine for drug development. Curr Opin Pharmacol 2011; 11: 501-7.
17. Roman S, Cusdin FS, Fonfria E, Goodwin JA, Reeves J, Lappin SC, Chambers L, Walter DS, Clay WC, Michel AD. Cloning and pharmacological characterization of the dog P2X7 receptor. Br J Pharmacol 2009; 158: 1513-26.
18. Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, Wang X, Gupta P, Mebus CA. Efficacy and safety of CE-224, 535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol 2012; 39: 720-727. DOI: 10.3899/jrheum.110874 (http://www.jrheum.org/content/early/2012/02/28/jrheum.110874).